Eli Lilly and Company (LLY)’in fiyatı nedir?

Eli Lilly and Company (LLY)’in fiyatı $1,133.97’dir

Eli Lilly and Company (LLY)’in piyasa değeri nedir?

Eli Lilly and Company (LLY)’in piyasa değeri $1.068T’dir.

Eli Lilly and Company (LLY) Tedavüldeki Hisseler

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Yıl	Tedavüldeki Hisse Sayısı	Değiştir
2026 (TTM)	892.40M	-0.62%
2025	898.00M	-0.29%
2024	900.61M	0.14%
2023	899.38M	-5.35%
2022	950.18M	-0.36%
2021	953.65M	-0.31%
2020	956.59M	-0.10%
2019	957.53M	-6.83%
2018	1.03B	-2.31%
2017	1.05B	-4.44%
2016	1.10B	-0.40%
2015	1.11B	-0.48%
2014	1.11B	-0.55%
2013	1.12B	-2.59%
2012	1.15B	2.92%
2011	1.11B	0.74%
2010	1.11B	0.68%
2009	1.10B	0.35%
2008	1.09B	0.37%
2007	1.09B	0.33%
2006	1.09B	-0.08%
2005	1.09B	0.35%
2004	1.08B	0.74%
2003	1.08B	-0.27%
2002	1.08B	0.12%
2001	1.08B	-0.28%
2000	1.08B	0.00%

Yıl

Tedavüldeki Hisse Sayısı

Değiştir

2026 (TTM)

892.40M

-0.62%

2025

898.00M

-0.29%

2024

900.61M

0.14%

2023

899.38M

-5.35%

2022

950.18M

-0.36%

2021

953.65M

-0.31%

2020

956.59M

-0.10%

2019

957.53M

-6.83%

2018

1.03B

-2.31%

2017

1.05B

-4.44%

2016

1.10B

-0.40%

2015

1.11B

-0.48%

2014

1.11B

-0.55%

2013

1.12B

-2.59%

2012

1.15B

2.92%

2011

1.11B

0.74%

2010

1.11B

0.68%

2009

1.10B

0.35%

2008

1.09B

0.37%

2007

1.09B

0.33%

2006

1.09B

-0.08%

2005

1.09B

0.35%

2004

1.08B

0.74%

2003

1.08B

-0.27%

2002

1.08B

0.12%

2001

1.08B

-0.28%

2000

1.08B

0.00%

Şirket	Tedavüldeki Hisse Sayısı	Fark	Ülke
Johnson & Johnson JNJ.US	2.44B	173.44%	US
AbbVie Inc. ABBV.US	1.77B	98.45%	US
Roche Holding AG RO.SW	796.00M	-10.80%	CH
Merck & Co., Inc. MRK.US	0.00	-100.00%	US
Novartis AG NOVN.SW	1.91B	114.37%	CH

Şirket

Tedavüldeki Hisse Sayısı

Fark

Ülke